Evaluation of treatment strategies for patients with stage IIIA non-small cell lung cancer in the immunotherapy era
Background: Optimal treatment for patients with stage IIIA NSCLC is controversial. Growing evidence indicates surgery with adjuvant or neoadjuvant chemotherapy (SC) may be superior to non-surgical treatments. Direct comparisons have not been performed between SC and chemoradiation with immunotherapy...
Saved in:
Main Authors: | Amy Alabaster, Jeffrey B. Velotta, Haley I. Tupper, Mark S. Walker, Yanina Natanzon |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-01-01
|
Series: | Cancer Treatment and Research Communications |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294224000649 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study
by: He Z, et al.
Published: (2025-01-01) -
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study
by: Laura Moliner, MD, et al.
Published: (2025-01-01) -
Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)
by: Mauro Zukin, et al.
Published: (2025-01-01) -
Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3)
by: Puco K, et al.
Published: (2025-01-01) -
Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer – real-world single-centre data
by: Bogdana Patachi, et al.
Published: (2025-01-01)